A 'Chemical Switch' Therapy Opens Less Toxic Ways to Treat Solid Cancers
3 Articles
3 Articles
Madrid, 4 Nov (EFE).- Researchers from several Spanish centers have verified (in animal models) that a cellular therapy adjustable through a ‘chemical switch’ can open the way to personalized and less toxic immunotherapies for the treatment of some solid cancers. It has been developed by the Research Group on Cancer Immunotherapy, a mixed group of the Hospital del Mar Research Institute (HMRIB) of Barcelona, the National Center for Oncological R…
A strategy of STAb-T immunotherapy allows to activate and regulate with a drug the antitumor activity of modified lymphocytes. Tested in animal models of haematological and solid tumors, it seeks to limit toxicity; its clinical utility must still be confirmed with safety studies and trials in patients. La entrada An adjustable cell therapy shows results in mice with solid and haematological tumors aparece primero en Merca2.
Treating cancer more effectively and with fewer side effects involves adjusting therapies to the unique features of each patient. Cell therapies are today the maximum form of personalization because they are manufactured by the patient's body: they are based on modifying immune cells - T lymphocytes - of the sick person himself, to enhance his ability to detect and destroy tumor cells. Cell therapies are already used in the clinic for some blood…
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
